remain bullish ahead rewind
continu like lilli posit given differenti growth
profil sever remain upsid driver play includ higher alimta volum
i/o combo lung better margin expans track beat long-term
revenu growth guidanc margin upsid elanco minim expect
migrain galcanezumab lasmiditan pain franchis
tanezumab long-term safeti data expect follow file
addit upcom rewind cardiovascular outcom studi readout
meaning event given contribut trulic growth profil lilli
diabet franchis overal end weve sever discuss
endocrinologist ahead rewind highlight detail start pg
view risk reward profil
favor share despit recent
out-performance maintain ow rate rais pt
trulic pois continu growth regardless outcom investor expect
mix ahead rewind data trulic continu well-posit
class view given uniqu design emphasi healthier well-
control diabet patient rewind challeng said feedback kol
posit expect favor cvot outcom support
good commerci experi trulic thu far inde clinic experi
also good reimburs profil drive continu share gain
trulic even mix rewind result non-inferior feedback
consist physician discuss survey henc share may
volatil mix rewind result wed still buyer given strong fundament
kol highlight recent opportun speak kol diabet
space key takeaway gener sentiment among kol rewind
like hit signific mix result unlik chang market dynam
neg outcome/demonstr harm highli unlik probabl
quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight exit yz period
new commerci stage portfolio attract diabet
oncolog immunolog asset model
forecast mid single-digit sale low double-digit
ep growth major
pharma averag execut product
cadenc think current multipl
faster expect commerci launch
expect jardianc trulic taltz
baricitinib could drive upsid potenti
re-rat biotech-lik multipl
slow uptak new diabet immunolog
margin pressur early/intermedi pipelin
failur could caus concern long term
lilli new product cycl among best biopharma
remain encourag growth profil go young
product cycl believ advanc top-lin growth quit time view
upsid lt guidanc compound-annual-growth-rate highli probabl growth
next two year need achiev lilli attract posit growth
larg driven new product launch volum growth underpin medium-
term outlook remain one favorit name pharma given differenti
growth profil steadi margin improv drive faster ep growth
lilli diabet franchis remain bull thesi
diabet remain mainstay lilli oper perform contribut total
revenu presum profit sale continu see
strength lilli overal diabet programwhich remain durabl despit overal
grow competit landscapeand current forecast compound-annual-growth-rate
key diabet franchis approxim figur view upcom
trulic rewind readout expect late could bolster diabet franchis
augment addit growth overal class see
trx growth agonist
see figur past month volum us base iqvia script
data outpac competitor product total volum recent
surpass combin victoza trx among trulic account
volum august januari figur
among differ diabet class insulin dpp-iv share experienc
greatest overal growth throughout last outpac expens
insulin dpp-iv contract figur accord manag
class grow believ class continu growth given
demonstr class-effect weight loss reduct well fact
larg under-prescrib
upon recent speak manag ceo/cfo seri learn
class like pois signific growth next sever year given
class current recogn patient fail oral option us
manag expect could easili expand come year base medic
need see takeaway ceo/cfo call replay inform includ
beyond us recogn even lower proport patient fail
oral regimen ou thu anticip continu class growth world-wide
think class pois lot growth recogn
one three patient fail oral option get glp could
doubl next year dave rick ceo
addit opportun speak kol regard rewind
class whole in-lin manag expect believ growth
class like continu undergo signific ramp market share potenti
doubl market penetr come year
progress growth almost inevit
competit group like compet market domin repres
group drug larg under-prescrib substanti
opportun growth wouldnt surpris year time market
rewind pois demonstr cv benefit
expect trulic demonstr statist signific cv risk reduct
upcom rewind readout note overal sentiment docs/kol
trial like achiev signific given larg size long durat trial
design like look increment reduct emphas
continu trial upon interim look late problemat view given
longer follow-up period believ lilli manag greater convict
current street expect potenti show superior given tendenc see
event secondari popul despit lower baselin base recent
discuss manag believ lilli remain rel unconcern regard
studi popul lower baselin vs cv outcom trial novo
leader sustain rather manag believ rewind trial design patient
adher dulaglutid trulic could show event secondari popul
demonstr separ curv given long-term follow
result rewind anticip even stronger adopt trulic well increas
overal growth broader class trial intend
real-world studi diabet patient less sever diseas repres popul
consist patient seen clinic practic wherea at-risk patient studi
cvot to-dat preval clinic practic thu expect posit
outcom yield immedi uptak along inevit share expans trial
target patient popul repres real-world clinic practic
rewind trial design superior competitor trial
comparison point
astrazeneca exscel trial figur like fail demonstr cv benefit due
number factor shorter follow-up short durat exposur high discontinu
rate use anti-diabet therapi reduc cv risk address
rewind trial design view rewind import catalyst maintain
trulic strong market posit novo oral semaglutid intermediate-
term lli oral program still nascent stage look readout
rewind pioneer cvot expect clarifi potenti
competit pictur within class though note believ oral
semaglutid erod meaning share trulic see
astrazeneca novo nordisk cover eu pharma analyst emmanuel papadaki
barclay research new england journal medicin annal translat medicin
non-inferior unlik impact trulic market posit
view even potenti mix outcom unlik derail trulic growth
ultim expect rewind yield posit result emphas mix result
reach statist signific demonstr non-inferior would still result
favor outcom trulic posit class overal recent
discuss kol larg focus current treatment paradigm potenti
market fluctuat follow upcom readout result conclus
anticip given mix result kol believ consider unlikelihood
unfavor impact trulic market posit suggest trulic continu
experi share expans long show harm patient popul
mix trial result wont neg impact trulic posit
class-effect belief prescrib pattern alreadi well-
establish current price paradigm quit lot
coverag trulic current prefer statu diabet kol
wide accept sentiment glp class-bas
previou public data large-scal trial evalu agonist
suggest may benefici class effect cardiovascular morbid
mortal accord kol seem share agreement among
kols/physician potenti class effect thu impress
class undergo continu growth even follow mix rewind outcom
continu expans overal class see room trulic continu strong
prescrib habit alreadi well-establish
physician patient alik seemingli comfort prescribing/us trulic
hold true regardless upcom trial result believ prescrib pattern
rewind exscelleadersustain lillyastrazenecanovo nordisknovo nordiskmoleculetrul dulaglutid bydureon exenatid victoza liraglutid ozemp semaglutid patient mean age mean age mean age mean age mg/wkpercent prior durat follow yearsdiscontinu ratestbdtot activ arm vs pbo patient decis activ arm vs pbo sae activ arm vs pboani ae activ arm vs pbo sae activ arm vs pboani ae activ arm vs pboresult tbdnon-inferior bydureon vs placebo term cv safeti superior placebo term efficaci superior cv death non-fatal mi stroke vs placebo cv death vs mi vs stroke vs death non-fatal mi stroke vs placebo cv death non-fatal mi vs non-fatal stroke vs barclay eli lilli co
play import role diabet space signific impact market
share compet product weekli dose better patient experi
devic help sustain franchis forese futur play role
preserv trulic growth profil
ozemp hard time establish market penetr
two trulic victoza alreadi establish diabet kol
result appar class-effect insur abil negoti
manufactur almost entir basi price devic certainli play role
negoti larg price discuss rather efficaci debat
physician may prefer deriv clinic evid often requir
prescrib treatment base prefer price
current price paradigm prefer trulic victoza highli
variabl individu insur clearli identifi tier prefer
quit lot coverag trulic diabet kol
discuss kol learn insur increasingli provid
group medicin manufactur novo lilli product group
togeth insur plan compani negoti access treatment group
basi rather drug-by-drug one accord kol major decis
pertain price remain base clinic endpoint devic
respect place emphasi fact current
system trulic prefer statu coverag widespread
oral sema limit overhang lack competit price
agre skeptic regard loom overhang novo oral semaglutid
warrant kol emphas sever issu face product could
ultim favor use trulic importantli price dynam order oral
sema wide adopt physician insur kol believ must price
steep discount price inject price similar level
inject howev like wont shift physician behavior pbm presum limit
access oral therapi
absent price inject likelihood oral sema
substanti adopt low peopl comfort current
therapi priorit alreadi use price big factor
diabet kol
kol anticip compani like over-estim appetit oral
agonist consequ inappropri price oral sema high level mayb
price point inject believ pretti close
continu look toward complet pioneer data see evid trial
potenti impact pbms/price dynam novo oral sema
admit neg outcom would like impact trulic share growth
potenti view rewind low likelihood show harm neg
trend estim chanc outcom state earlier
readout ultim yield rel mix result would maintain bullish stanc
trulic lilli overal diabet franchis given underwhelm rewind
outcom would seemingli off-set continu robust growth overal
class see analysi
probabl trulic show harm id say somewher
low singl digit havent seen indic glp caus harm
trulic caus harm would someth realli surpris risk
harm id probabl put mayb chanc diabet kol
beyond class growth believ trulic solid posit weekli dose
patient/physician familiar strong complianc demonstr current demand
continu bolster growth profil remain bullish compani overal diabet
franchis regardless result although reiter potenti sizeabl rapid
revis price target reflect blend averag price
earn multipl analysi assum current year multipl sustain forward
year earn impli per share vs prior dcf also
impli intrins valu per share vs prior
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
